약물감시 시장 : 컴포넌트, 유형, 제품 수명 주기, 제공 형태, 프로세스 플로우, 용도, 최종 사용자, 도입 모델별 예측(2026-2032년)

The Pharmacovigilance Market is projected to grow by USD 34.17 billion at a CAGR of 16.34% by 2032.

Pharmacovigilance Market Introduction

Pharmacovigilance has moved from a back-office compliance function to a strategic capability for protecting patients, preserving product value, and meeting global drug safety obligations. As regulators expand expectations for adverse event reporting, risk management plans, periodic benefit-risk evaluation reports, and post-marketing surveillance, life sciences organizations are prioritizing faster case intake, stronger signal detection, and auditable safety governance.

The pharmacovigilance landscape is shaped by rising medicine utilization, complex biologics and vaccines, expanding clinical trial activity, and larger volumes of real-world safety data from electronic health records, claims, patient support programs, call centers, literature, social media, and digital health channels. Organizations that can convert these data streams into validated individual case safety reports, risk signals, and compliant regulatory submissions are better positioned to maintain inspection readiness, strengthen benefit-risk management, and improve patient outcomes.

Transformative Shifts in the Pharmacovigilance Landscape

The pharmacovigilance landscape is being transformed by regulatory harmonization, digitized safety operations, and a shift toward proactive benefit-risk management. Standards such as ICH E2B(R3), MedDRA coding, EU Good Pharmacovigilance Practices, FDA post-market reporting expectations, and WHO safety monitoring principles are encouraging more structured, interoperable, and traceable safety data exchange across global safety systems.

At the same time, safety teams are absorbing higher reporting volumes from specialty drugs, biologics, vaccines, combination products, social listening programs, digital therapeutics, telehealth, and patient engagement platforms. This is pushing sponsors and service providers to redesign operating models around automation, quality-by-design, global case processing hubs, local affiliate oversight, medical safety review, and integrated signal management to support timely regulatory compliance and patient safety decisions.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is having a cumulative impact across pharmacovigilance by improving the speed, consistency, and traceability of routine workflows. Natural language processing, machine learning classification, entity extraction, duplicate detection, automated narrative drafting, intelligent MedDRA coding, and literature screening can reduce manual effort in case intake, triage, and quality control when implemented with validated rules and human oversight.

The strongest use cases are emerging where AI supports, rather than replaces, qualified safety professionals. Regulators continue to expect explainability, audit trails, documented validation, data privacy safeguards, and medical judgment for causality assessment, seriousness evaluation, expectedness review, and signal detection. As a result, AI adoption is most effective when embedded in governed safety systems that align with GxP quality standards, risk-based validation, cybersecurity controls, and transparent change management.

Key Regional Insights for Pharmacovigilance

Asia-Pacific is gaining importance as China, India, Japan, South Korea, Australia, and ASEAN markets expand clinical development, generic and biosimilar manufacturing, and national adverse event reporting systems. Regulatory authorities across the region are increasing expectations for local case reporting, risk management, and post-authorization safety monitoring, making regional pharmacovigilance coordination critical for sponsors operating across diverse languages, formats, and timelines. North America remains a mature center for pharmacovigilance innovation, supported by FDA FAERS, the Sentinel Initiative, REMS oversight, Health Canada reporting requirements, extensive clinical research activity, and established life sciences outsourcing capacity.

Latin America is strengthening post-marketing surveillance as Brazil, Mexico, and other markets modernize regulatory procedures and increase local safety reporting expectations. Europe continues to set a high bar through the European Medicines Agency, EudraVigilance, EU Good Pharmacovigilance Practices, formal risk management planning, and periodic safety reporting obligations. The Middle East is advancing national pharmacovigilance centers, electronic reporting, and local safety responsibilities as healthcare systems digitalize, while Africa is building medicine safety capacity through national regulatory authorities, WHO program participation, adverse event monitoring for vaccines and essential medicines, and stronger reliance-based regulatory collaboration as medicine access expands.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly aligned around regional reliance, local safety reporting, pharmacovigilance capacity building, and regulatory cooperation, making the bloc important for companies seeking scalable Asia-Pacific safety models. The GCC is advancing medicine safety oversight across Gulf states through regulatory coordination, hospital reporting systems, national health strategies, and digital health investments that generate more structured safety data for post-marketing surveillance.

The European Union remains the global benchmark for rigorous pharmacovigilance governance through centralized procedures, EudraVigilance, legally defined responsibilities for marketing authorization holders, qualified person requirements, and EU Good Pharmacovigilance Practices. BRICS countries represent strategically important demand because of large patient populations, domestic pharmaceutical manufacturing, expanding clinical research participation, and maturing surveillance systems. G7 markets continue to shape advanced standards for data integrity, inspection readiness, AI governance, real-world evidence, and benefit-risk transparency, while NATO countries add relevance through health security, medical countermeasure monitoring, supply resilience, and safety surveillance for critical medicines used in emergency preparedness.

Key Country Insights in Global Pharmacovigilance

The United States leads in large-scale post-market surveillance through FDA FAERS, Sentinel, REMS oversight, mandatory reporting obligations, and a mature ecosystem of pharmaceutical sponsors and safety service providers. Canada maintains strong pharmacovigilance requirements through Health Canada and its adverse reaction reporting framework, while Mexico and Brazil are important Latin American markets as COFEPRIS and ANVISA continue to strengthen medicine safety oversight, regulatory modernization, and local reporting practices.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to clinical development, regulatory science, medical literature monitoring, and EU-aligned safety operations, with the United Kingdom operating through the MHRA and Yellow Card Scheme and EU members contributing to EudraVigilance-based surveillance. Russia requires localized regulatory attention due to national reporting expectations and local regulatory procedures. China and India are critical because of their scale in clinical research, manufacturing, pharmacovigilance program development, and patient populations; Japan and South Korea combine advanced regulatory systems with high adoption of structured safety data standards and strong post-marketing obligations; and Australia offers a mature, transparent system under the Therapeutic Goods Administration that supports regional pharmacovigilance planning across Asia-Pacific.

Actionable Recommendations for Pharmacovigilance Leaders

Industry leaders should prioritize a risk-based pharmacovigilance operating model that connects global safety databases, local affiliate processes, medical review, quality management, signal detection, and regulatory intelligence. Investing in interoperable platforms that support ICH E2B(R3), standardized MedDRA coding, automated case routing, literature screening, duplicate detection, audit trails, and compliant submissions can reduce cycle times while improving data quality and inspection readiness.

Organizations should also establish AI governance before scaling automation. Practical actions include validating algorithms, documenting model performance, preserving human medical oversight, monitoring bias, integrating privacy controls, maintaining vendor oversight, and training safety teams to work with intelligent workflow tools. Vendor partnerships should be assessed on inspection history, pharmacovigilance domain expertise, data security, multilingual coverage, regulatory submission capability, business continuity, and measurable quality outcomes.

Research Methodology

This executive summary is based on secondary research from publicly available regulatory guidance, international safety standards, national pharmacovigilance frameworks, and established industry practices. Core reference points include FDA post-marketing safety systems, EMA and EU GVP requirements, WHO pharmacovigilance principles, ICH safety data standards, MedDRA terminology practices, and country-level regulatory authority guidance.

The analysis applies a qualitative market intelligence approach, evaluating regulatory maturity, adverse event reporting infrastructure, technology adoption, outsourcing trends, clinical development activity, safety database interoperability, inspection expectations, and regional policy direction. Insights were synthesized to support strategic decision-making for pharmaceutical manufacturers, biotechnology companies, contract research organizations, pharmacovigilance service providers, medical affairs teams, and digital safety platform vendors without applying market sizing, market share, or forecast assumptions.

Conclusion

Pharmacovigilance is entering a more data-intensive and intelligence-led era in which speed, accuracy, interoperability, and transparency define operational advantage. Organizations that build modern safety architectures will be better prepared to manage global reporting complexity, detect emerging risks earlier, support compliant benefit-risk decisions, and maintain trusted relationships with regulators, clinicians, and patients.

As AI, real-world evidence, structured data standards, and harmonized regulatory expectations continue to mature, pharmacovigilance will increasingly support enterprise-wide benefit-risk strategy rather than isolated compliance tasks. Leaders that combine technology with medical expertise, quality discipline, validated governance, and regional regulatory intelligence can create resilient safety systems for the next generation of medicines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmacovigilance Market, by Component

• 7.1. Software
• 7.2. Services

8. Pharmacovigilance Market, by Type

• 8.1. Cohort Event Monitoring
• 8.2. EHR Mining
• 8.3. Intensified ADR Reporting
• 8.4. Spontaneous Reporting
• 8.5. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by Product Life Cycle

• 9.1. Phase I
• 9.2. Phase II
• 9.3. Phase III
• 9.4. Phase IV
• 9.5. Pre-clinical

10. Pharmacovigilance Market, by Delivery Mode

• 10.1. In-house
• 10.2. Outsourced

11. Pharmacovigilance Market, by Process Flow

• 11.1. Case Data Management
  • 11.1.1. Case Data Analysis
  • 11.1.2. Case Logging
  • 11.1.3. Medical Reviewing & Reporting
• 11.2. Risk Management System
  • 11.2.1. Risk Evaluation System
  • 11.2.2. Risk Mitigation System
• 11.3. Signal Detection
  • 11.3.1. Adverse Event Analysis
  • 11.3.2. Adverse Event Logging
  • 11.3.3. Adverse Event Review & Reporting

12. Pharmacovigilance Market, by Application

• 12.1. Cardiovascular
• 12.2. Infectious Diseases
• 12.3. Neurology
• 12.4. Oncology
• 12.5. Respiratory

13. Pharmacovigilance Market, by End-user

• 13.1. Biotechnology Companies
• 13.2. Medical Device Manufacturers
• 13.3. Pharmaceuticals

14. Pharmacovigilance Market, by Deployment Model

• 14.1. On-Premises
• 14.2. Cloud-Based
• 14.3. Hybrid

15. Pharmacovigilance Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Pharmacovigilance Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Pharmacovigilance Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Accenture, PLC
• 19.2. Bristol-Myers Squibb Company
• 19.3. Capgemini SE
• 19.4. ClinChoice
• 19.5. F. Hoffmann-La Roche AG
• 19.6. GlaxoSmithKline PLC
• 19.7. HCL Technologies Limited
• 19.8. ICON PLC
• 19.9. Infosys Limited
• 19.10. International Business Machines Corporation
• 19.11. IQVIA Inc.
• 19.12. ITclinical
• 19.13. Linical Co., Ltd.
• 19.14. Novartis AG
• 19.15. Oracle Corporation
• 19.16. Parexel International
• 19.17. Pfizer Inc.
• 19.18. Quanticate International limited
• 19.19. Sanofi S.A.
• 19.20. Syneos Health
• 19.21. TAKE Solutions Limited
• 19.22. TATA Consultancy Services Limited
• 19.23. Wipro Limited